Skip to main content

Advertisement

Table 3 Optimal EBV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein HLA Restriction Sequence Position Reference
BMLF1 A1 LVSDYCNVLNKEFT 25–39 [27]
BMLF1 A2 GLCTLVAML 280–288 [28]
BMLF1 B18 DEVEFLGHY 397–405 [28]
BMLF1 n.d.* KDTWLDARM 265–273 [29]
BMLF1 A24 DYNFVKQLF 320–328 [30]
BHRF A2 LLWAARPRL 204–212 [31]
BZLF1 B7 LPCVLWPVL 44–52 [13]
BZLF1 B8 RAKFQLL 190–197 [32]
BZLF1 Cw6 RKCCRAKFKQLLQH 186–201 [1]
BMRF1 Cw6 YRSGIIAW 268–276 [16]
BMRF1 Cw3 FRNLAYGRTCVLGK 86–100 [16]
BRLF1 A2 YVLDHLIVV 109–117 [33]
BRLF1 A2 RALIKTLPRASYSSH 225–239 [27]
BRLF1 A3 RVRAYTYSK 148–156 [1]
BRLF1 A11 ATIGTAMYK 134–142 [16]
BRLF1 A24 DYCNVLNKEF 28–37 [27]
BRLF1 A24 TYPVLEEMF 198–206 [30]
BRLF1 B61 QKEEAAICGQMDLS 529–543 [1]
BRLF1 Cw4 ERPIFPHPSKPTFLP 393–407 [1]
gp110 A2 ILIYNGWYA 106–114 [1]
gp110 B35 VPGSETMCY 544–552 [1]
gp110 B35 APGWLIWTY 190–198 [1]
gp85 A2 TLFIGSHVV 420–428 [1]
gp85 A2 LMPIIPLINV 542–550 [1]
gp85 A2 SLVIVTTFV 225–233 [1]
gp350 A2 VLQWASLAV 863–871 [1]
gp350 A2 VLTLLLLLV 871–879 [34]
gp350 A2 LIPETVPYI 152–160 [34]
gp350 A2 QLTPHTKAV 67–75 [34]
EBNA1 A2 FMVFLQTHI 562–570 [13]
EBNA1 B7 RPQKRPSCI 72–80 [35]
EBNA1 B7 IPQCRLTPL 528–536 [35]
EBNA1 B53 HPVGEADYF 407–415 [35]
EBNA2 A2/B51 DTPLIPLTIF 42–50 [36]
EBNA3A A2 SVRDRLARL 596–604 [37]
EBNA3A A3 RLRAEAQVK 603–611 [38]
EBNA3A A24 RYSIFFDY 246–253 [37]
EBNA3A A29 VFSDGRVAC 491–499 [16]
EBNA3A A30 AYSSWMYSY 176–184 [1]
EBNA3A B7 RPPIFIRRL 379–387 [39]
EBNA3A B7 VPAPAGPIV 502–510 [16]
EBNA3A B8 QAKWRLQTL 158–166 [37]
EBNA3A B8 FLRGRAYGL 325–333 [40]
EBNA3A B35 YPLHEQYGM 458–466 [37]
EBNA3A B46 VQPPQLTLQV 617–625 [41]
EBNA3A B62 LEKARGSTY 406–414 [16]
EBNA3A n.d.* HLAAQGMAY 318–326 [16]
EBNA3B A1l NPTQAPVIQLHAVY 101–115 [40]
EBNA3B A1l AVFDRKSDAK 399–408 [16]
EBNA3B A1l LPGPQVTAVLLHEES 481–495 [40]
EBNA3B A1l DEPASTEPVHDQLL 551–563 [40]
EBNA3B Al1 IVTDFSVIK 416–424 [40]
EBNA3B A24 TYSAGIVQI 217–225 [16]
EBNA3B A27 RRARSLSAERY 243–253 [42]
EBNA3B B35 AVLLHEESM 488–496 [1]
EBNA3B B44 VEITPYKPTW 657–666 [16]
EBNA3B B58 VSFIEFVGW 279–287 [43]
EBNA3B B62 GQGGSPTAM 831–839 [16]
EBNA3C B7 QPRAPIRPI 881–889 [39]
EBNA3C B27 RRIYDLIEL 258–266 [44]
EBNA3C B27 HRCQAIRK 149–157 [16]
EBNA3C B27 FRKAQIQGL 343–351 [16]
EBNA3C B27 RKIYDLIEL 258–266 [45]
EBNA3C B27 RRIFDLIEL 258–266 [45]
EBNA3C B27 LRGKWQRRYR 249–258 [44]
EBNA3C B37 LDFVRFMGV 285–293 [46]
EBNA3C B39 HHIWQNLL 271–278 [16]
EBNA3C B44 KEHVIQNAF 335–343 [47]
EBNA3C B44 EENLLDFVRF 281–290 [40]
EBNA3C B44 EGGVGWRHW 163–171 [48]
EBNA3C B62 QNGALAINTF 213–222 [49]
EBNALP A2 SLREWLLRI 284–292 [43]
LMP1 A2 YLQQNWWTL 159–167 [50]
LMP1 A2 YLLEMLWRL 125–133 [50]
LMP1 A2 LLVDLLWLL 167–175 [50]
LMP1 A2 TLLVDLLWL 166–174 [50]
LMP1 A2 LLLIALWNL 92–100 [50]
LMP1 B51 DPHGPVQLSYYD 393–404 [51]
LMP2 A2 FLYALALLL 356–364 [52]
LMP2 A2 LLWTLWLL 329–337 [53]
LMP2 A2 CLGGLLTMV 426–434 [54]
LMP2 A2 LTAGFLIFL 453–461 [53]
LMP2 A11 SSCSSCPLSKI 340–350 [53]
LMP2 A23 PYLFWLAAI 131–139 [55]
LMP2 A2 LLSAWILTA 447–455 [43]
LMP2 A24 TYGPVFMCL 419–427 [53]
LMP2 A24 IYVLVMLVL 222–230 [30]
LMP2 A25 VMNSNTLLSAW 442–451 [16]
LMP2 A27 RRRWRRLTV 236–244 [44]
LMP2 B40 IEDPPFNSL 200–208 [53]
LMP2 B63 WTLWLLI 331–338 [1]
  1. *not determined